Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79832.410.0103%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Cytokinetics Inc

CYTKNASDAQ
Trade with Public
Trade with Public
$72.72
-1.23-1.66%
At close: Sep 4, 5:00 PM EST
$72.72
N/A
After Hours: Sep 4, 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Cytokinetics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cytokinetics (CYTK).

Price Target Range — 9 Quarters

Analyst Consensus — 21 Analysts

3S.Buy
17Buy
1Hold
Consensus RatingBuy# Analysts21Avg. Consensus PT$99Upside to Avg. PT+36.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 31, 2026HC Wainwright & Co.Joseph PantginisMaintainedBuy$140
Aug 13, 2026BarclaysEmily FieldPT RaiseOverweight$95→$110
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $140 price target.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $110

Barclays analyst Emily Field maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $95 to $110.
Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $103

JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $97 to $103.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Cytokinetics, Raises Price Target to $112

Truist Securities analyst Srikripa Devarakonda maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $106 to $112.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $112

RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and lowers the price target from $117 to $112.
Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Cytokinetics, Raises Price Target to $110

Citizens analyst Jason N. Butler maintains Cytokinetics (NASDAQ:CYTK) with a Market Outperform and raises the price target from $105 to $110.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved